Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 7:29 AM ET

Biotechnology

Company Overview of VBI Vaccines Inc

Company Overview

VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

222 Third Street

Suite 2241

Cambridge, MA 02142

United States

18 Employees

Phone:

617-830-3031

Key Executives for VBI Vaccines Inc

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $350.0K
Chief Financial Officer
Age: 48
Total Annual Compensation: $198.0K
Senior Vice President of Research
Age: 43
Total Annual Compensation: $220.0K
Vice President of Formulation Development
Age: 51
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2013.

VBI Vaccines Inc Key Developments

VBI Vaccines, Inc. Announces New Data Supporting the Manufacture of Prophylactic CMV Vaccine Candidate

VBI Vaccines Inc. provided an update on the progress of its cytomegalovirus vaccine development program on April 8, 2015 at the World Vaccine Congress 2015 in Washington, D.C. Dr. David E. Anderson, company's Senior Vice President of Research, presented new data from interim yield and purity testing of VBI-1501A, company's prophylactic CMV vaccine candidate, which is now being manufactured in quantities needed for planned toxicology, stability, and clinical studies. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines. eVLPs are a new class of vaccines that are designed to resemble the structure of viruses, but do not contain any potentially infectious viral material. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. During recent testing, the company employed electron microscopy to confirm the integrity of the eVLP particles (drug substance) used to create VBI-1501A. A separate in vivo potency assay assessed the consistency and potency of multiple batches of VBI-1501A, with positive interim results. Purity measurements are expected to meet regulatory requirements for clinical evaluation of the vaccine candidate. The company plans to initiate formal toxicology studies in the second quarter of 2015.

VBI Vaccines Inc. enters into research collaboration with Sanofi Pasteur

VBI Vaccines Inc. announced that it entered into a research collaboration with Sanofi Pasteur to develop a more stable version of a key Sanofi Pasteur vaccine candidate using its Lipid Particle Vaccine formulation technology. VBI Vaccines announced that the collaboration agreement provides Sanofi Pasteur with an option to acquire certain worldwide rights to use the LPV technology in its vaccines.

VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM

VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Phyllom BioProducts Corporation United States
Toshiba Medical Research Institute USA, Inc. United States
Cell-Matrix, Inc. United States
REGENX Biosciences, LLC United States
Protagonist Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 9, 2014
Paulson Capital (Delaware) Corp.
Private Placement
May 8, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VBI Vaccines Inc, please visit www.vbivaccines.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.